- Home
- AVTX vs RSF Comparison
AVTX vs RSF Comparison
Compare AVTX & RSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- RSF
- Stock Information
- Founded
- AVTX 2011
- RSF 2016
- Country
- AVTX United States
- RSF United States
- Employees
- AVTX N/A
- RSF N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- RSF Investment Managers
- Sector
- AVTX Health Care
- RSF Finance
- Exchange
- AVTX Nasdaq
- RSF Nasdaq
- Market Cap
- AVTX 57.4M
- RSF 49.1M
- IPO Year
- AVTX 2015
- RSF N/A
- Fundamental
- Price
- AVTX $4.89
- RSF $14.69
- Analyst Decision
- AVTX Strong Buy
- RSF
- Analyst Count
- AVTX 7
- RSF 0
- Target Price
- AVTX $31.00
- RSF N/A
- AVG Volume (30 Days)
- AVTX 82.2K
- RSF 11.8K
- Earning Date
- AVTX 08-11-2025
- RSF 01-01-0001
- Dividend Yield
- AVTX N/A
- RSF 10.61%
- EPS Growth
- AVTX N/A
- RSF N/A
- EPS
- AVTX N/A
- RSF N/A
- Revenue
- AVTX $441,000.00
- RSF N/A
- Revenue This Year
- AVTX N/A
- RSF N/A
- Revenue Next Year
- AVTX N/A
- RSF N/A
- P/E Ratio
- AVTX N/A
- RSF N/A
- Revenue Growth
- AVTX N/A
- RSF N/A
- 52 Week Low
- AVTX $3.39
- RSF $14.81
- 52 Week High
- AVTX $16.00
- RSF $16.23
- Technical
- Relative Strength Index (RSI)
- AVTX 54.89
- RSF 50.55
- Support Level
- AVTX $4.63
- RSF $14.52
- Resistance Level
- AVTX $5.02
- RSF $14.94
- Average True Range (ATR)
- AVTX 0.27
- RSF 0.11
- MACD
- AVTX 0.00
- RSF 0.02
- Stochastic Oscillator
- AVTX 72.73
- RSF 45.24
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.